Clinical Trial Update: Safety Study of Raltegravir in HIV/HCV Co-infected Patients [Phase 4]

View source ↗

Summary

A Phase 4 safety study of raltegravir in patients co-infected with HIV and hepatitis C has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: University Hospital, Bonn | Conditions: HIV, Hepatitis C | Phase 4 | Status: WITHDRAWN